Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / GNNSF - Week In Review: Nanjing Legend Files To Stage IPO In The U.S.


GNNSF - Week In Review: Nanjing Legend Files To Stage IPO In The U.S.

Deals and Financings

Nanjing Legend Biotech, a subsidiary of GenScript (HK: 1548) (GNNSF), has filed for an IPO on a US exchange. In 2017, Legend surprised the world when its CAR-T therapy produced a 94% response rate in pretreated multiple myeloma patients. Six months later, Johnson & Johnson (JNJ) partnered the treatment in a deal that paid Legend $350 million upfront, plus unspecified milestones and royalties. The CAR-T candidate, JNJ-4528, is now in Phase II trials in the US.

Harbour BioMed ((HBM)) raised $75 million in a Series B+ round to advance its clinical-stage compounds

Read more ...

Stock Information

Company Name: Genscript Biotech Corp
Stock Symbol: GNNSF
Market: OTC

Menu

GNNSF GNNSF Quote GNNSF Short GNNSF News GNNSF Articles GNNSF Message Board
Get GNNSF Alerts

News, Short Squeeze, Breakout and More Instantly...